-+ 0.00%
-+ 0.00%
-+ 0.00%

Eledon Q1 FY26 net loss widens to $39.03 million

PUBT·05/13/2026 20:12:00
Listen to the news
Eledon Q1 FY26 net loss widens to $39.03 million
  • Eledon Pharmaceuticals posted a Q1 net loss of USD 39 million, or USD 0.33 per share, versus a net loss of USD 6.5 million, or USD 0.08 per share, a year earlier.
  • Operating loss widened to USD 21.18 million as R&D expense climbed to USD 17.2 million from USD 13.5 million.
  • Cash, cash equivalents, short-term investments fell to USD 111.1 million as of March 31 from USD 133.3 million at end-2025; runway seen into 2Q 2027.
  • Non-cash loss from warrant liability fair-value changes was USD 19 million; excluding those items, net loss was USD 20.1 million.
  • Reported 100% insulin independence in 10 islet-transplant patients treated with tegoprubart, received FDA orphan-drug designation in liver transplantation, and expects FDA guidance in 2026 to support Phase 3 planning in kidney transplantation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605131605PRIMZONEFULLFEED9719791) on May 13, 2026, and is solely responsible for the information contained therein.